Diasorin SpA
DIA
Company Profile
Business description
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin’s largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).
Contact
Via Crescentino Snc
Saluggia
Vercelli13040
ITAT: +39 1614871
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2024
Employees
3,186
Stocks News & Analysis
stocks
Should you invest in small caps?
With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio.
stocks
3 no moat companies that might surprise you
Moats are rare but worth looking for. These three ASX listed companies own iconic brands but don't make the cut according to our analysts.
stocks
Are investors too optimistic about ASX listed data centre provider?
Move to cloud and AI driving strong data centre industry demand.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,659.60 | 47.00 | 0.55% |
| CAC 40 | 7,123.33 | 71.18 | -0.99% |
| DAX 40 | 19,220.09 | 75.89 | -0.39% |
| Dow JONES (US) | 44,860.31 | 123.74 | 0.28% |
| FTSE 100 | 8,264.72 | 6.11 | 0.07% |
| HKSE | 19,603.13 | 443.93 | 2.32% |
| NASDAQ | 19,175.58 | 120.74 | 0.63% |
| Nikkei 225 | 38,134.97 | 307.03 | -0.80% |
| NZX 50 Index | 13,212.92 | 99.16 | 0.76% |
| S&P 500 | 6,021.63 | 34.26 | 0.57% |
| S&P/ASX 200 | 8,406.70 | 47.30 | 0.57% |
| SSE Composite Index | 3,309.78 | 50.02 | 1.53% |